The FERO Women’s Cancer Grant 2027 provides €100,000 over two years for translational research in breast, ovarian, endometrial, cervical, and other gynaecological cancers. The grant supports original projects that could lead to better diagnostic methods or treatments and improve survival or quality of life.
Researchers of any nationality may apply, provided they meet the requirements for leading a research group and holding an institutional affiliation in Spain by the time of the award. Applicants first submit a short proposal; only shortlisted teams are invited to submit a full application.
Eligibility Criteria
- Hold a PhD, a cancer-related clinical specialty obtained through Spain’s MIR programme, or both.
- Demonstrate a track record in women’s cancer research and in translational oncology with potential clinical application.
- Lead a research group at an eligible research centre in Spain by the time the award is made.
- Hold an affiliation or contract with an eligible nonprofit institution in Spain by the award date. If the appointment is pending at application, include a signed commitment letter from the host.
- Have secured competitive funding as principal investigator for at least one research, development, or innovation project in the past three years.
- Propose original work that has not already received funding for the same activities. Submit only one proposal to this call.
Funding Details
- Award: €100,000 over two years.
- Number of awards: One planned.
- Indirect costs: Up to 5% of eligible direct costs, excluding external services and subcontracting from the calculation.
Deadline
- Short proposal: November 13, 2026, at 3:00 p.m. CET. The proposal must be in English and no more than three pages.
- Shortlist notification: December 18, 2026.
- Invited full proposal: January 29, 2027, at 3:00 p.m. CET.
- Expected decision: Late March 2027.